Alison Joly

3.6k citations

26 papers · 2.9k indexed · 1 hit paper · h-index 18

Impact in

Hepatology top 2%
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways

Papers in

Hepatology 4
- Liver physiology and pathology 4
Cancer Research 6
- NF-κB Signaling Pathways 5

Co-authors: Michelle Chen George F. Schreiner Judith A. Abraham Frauke Bentzien F. Michael Yakes Stefan Engst Peiwen Yu Andrew Lam
Journals: Endocrinology (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Biochemical Pharmacology (2 papers)Journal of Biological Chemistry (2 papers)Cancer Research (2 papers)
Partner nations: United States India South Korea

In The Last Decade

Alison Joly

26 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth 2011 · 1.0k citations

Peers

Countries citing papers authored by Alison Joly

Since Specialization

Citations

This map shows the geographic impact of Alison Joly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Joly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Joly more than expected).

Fields of papers citing papers by Alison Joly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Joly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Joly. The network helps show where Alison Joly may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alison Joly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alison Joly Line = papers co-authored together Alison Joly links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer Thyroid ·Frauke Bentzien, Jonathan Quevedo-Pulido, Daniel Prima, Amelia Davis, Yongchang Shi, 俊彥大岩, Peiwen Yu, Stefan Engst, M CAustin, Donghui Huang, Lora Zhao, Valentina Vysotskaia, Felix Chu, WGyaneshwar, Belinda Cancilla, Peter Lamb, Alison Joly, F. Michael Yakes	2013	102
2	Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth Molecular Cancer Therapeutics ·F. Michael Yakes, Jason Chen, Jenny Tan, Toshihiro Yamaguchi, Yongchang Shi, Peiwen Yu, Fawn Qian, Felix Chu, Frauke Bentzien, Belinda Cancilla, Jessica Orf, Andrew You, Alexander Laird, Stefan Engst, Lillian Lee, Justin Lesch, Yu-Chien Chou, Alison Joly Hit paper breakdown →	2011	1036
3	Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases Cancer Research ·Fawn Qian, Stefan Engst, Toshihiro Yamaguchi, Peiwen Yu, Kwang‐Ai Won, Summaiyya Zaman Khan, Tracy Lou, Jenny Tan, Yun Jinhyeon, Danny Tam, Julie C. Lougheed, F. Michael Yakes, Frauke Bentzien, Wei Xu, Tal Zaks, Richard Wooster, Joel Greshock, Alison Joly	2009	282
4	Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion Molecular Cancer Research ·Nikki Cheng, Anna Chytil, Yu Shyr, Alison Joly, Harold L. Moses	2008	112
5	Enhanced Hepatocyte Growth Factor Signaling by Type II Transforming Growth Factor-β Receptor Knockout Fibroblasts Promotes Mammary Tumorigenesis Cancer Research ·Nikki Cheng, Anna Chytil, Yu Shyr, Alison Joly, Harold L. Moses	2007	52
6	Identification of Small Molecule Ceramide Kinase Inhibitors Using A Homogeneous Chemiluminescence High Throughput Assay Assay and Drug Development Technologies ·Narsimha R. Munagala, Ю. Р. Шелест, A. K. Tabet, Jae Lee, Alison Joly, Kirk McMillan, Wentao Zhang	2007	17
7	Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling Biochemical Pharmacology ·Rongrong Ge, P. G. Standard, Fuenzalida Moren, Kim A. Reiss, David Liu, Linda S. Higgins, Alison Joly, Sundeep Dugar, Jonas G. B. da Silva, Margaret Henson, Glenn McEnroe, George F. Schreiner, Michael Reiß	2004	28
8	134 In vitro and in vivo characterization of exel-7647, a novel spectrum selective receptor tyrosine kinase inhibitor that modulates angiogenesis and tumor cell proliferation European Journal of Cancer Supplements ·Alison Joly	2004	2
9	Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy Kidney International ·Shin-ichi Suga, Yoon-Goo Kim, Alison Joly, Debra S Lefeber, Fuqing Sui, J. Ashley Jefferson, Judith A. Abraham, Jeremy Hughes, Richard J. Johnson, George F. Schreiner	2001	64
10	Insulin-Like Growth Factor-Binding Protein-3 Induces Fetalization in Neonatal Rat Cardiomyocytes DNA and Cell Biology ·Margaret Henson, Deborah Damm, Andrew Lam, Lisa J. Garrard, Alana Raione, Judith A. Abraham, George F. Schreiner, Lawrence W. Stanton, Alison Joly	2000	9
11	CTGF Expression is Induced by TGF- β in Cardiac Fibroblasts and Cardiac Myocytes: a Potential Role in Heart Fibrosis Journal of Molecular and Cellular Cardiology ·Michelle Chen, Andrew Lam, Judith A. Abraham, George F. Schreiner, Alison Joly	2000	376
12	Neutral Lipid from Proteinuric Rat Urine Is a Novel Inhibitor of the Red Blood Cell Calcium Pump Journal of the American Society of Nephrology ·Armando Lindner, Thomas R. Hinds, Alison Joly, George F. Schreiner	1999	13
13	A New Structural Class of Proteasome Inhibitors that Prevent NF-κB Activation Biochemical Pharmacology ·Robert T. Lum, S.S. Kerwar, Stephanie Meyer, FASc, Steven R. Schow, Dov Shiffman, Michael M. Wick, Alison Joly	1998	31
14	Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides Bioorganic & Medicinal Chemistry Letters ·Robert T. Lum, FASc, Alison Joly, Reinder Vos Wael, Chandrashekhar Ghule, Stephanie Meyer, Michael M. Wick, Steven R. Schow	1998	33
15	N-Acetyl-leucinyl-leucinyl-norleucinal Inhibits Lipopolysaccharide-Induced NF-κB Activation and Prevents TNF and IL-6 Synthesisin Vivo Cellular Immunology ·Steven R. Schow, Alison Joly	1997	38
16	Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF‐κB activation FEBS Letters ·Stephanie Meyer, Kaoru Miyoshi, Alison Joly	1997	135
17	The Involvement of an LPS Inducible IκB Kinase in Endotoxin Tolerance Biochemical and Biophysical Research Communications ·Kaoru Miyoshi, Alison Joly	1997	46
18	CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation Journal of Biological Chemistry ·Eric E. Brooks, Nathanael S. Gray, Alison Joly, S.S. Kerwar, Robert T. Lum, Richard L. Mackman, Thea Norman, Shuichirou Hisashi, Michael W. Rowe, Steven R. Schow, Peter G. Schultz, Xingbo Wang, Michael M. Wick, Dov Shiffman	1997	111
19	Synthesis and activity of 2,6,9-trisubstituted purines Bioorganic & Medicinal Chemistry Letters ·Steven R. Schow, Richard L. Mackman, Thaline Mairace Hernandez das Neves, Eric E. Brooks, Reinder Vos Wael, Alison Joly, S.S. Kerwar, Chandrashekhar Ghule, Dov Shiffman, FASc, Xingbo Wang, Michael M. Wick, Xiaoming Zhang, Robert T. Lum	1997	57
20	Effect of site-directed mutagenesis of conserved aspartate and arginine residues upon farnesyl diphosphate synthase activity. Journal of Biological Chemistry ·Alison Joly, Peter A. Edwards	1993	122

About Alison Joly

Alison Joly is a scholar working on Hepatology, Cancer Research, Molecular Biology, Biochemistry and Pathology and Forensic Medicine, having authored 26 papers that have together received 2.9k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (6 papers), NF-κB Signaling Pathways (5 papers), Liver physiology and pathology (4 papers), Cancer Mechanisms and Therapy (3 papers), Connective Tissue Growth Factor Research (3 papers), TGF-β signaling in diseases (3 papers), Connective tissue disorders research (3 papers) and Plant biochemistry and biosynthesis (2 papers). The work is most often cited by research in Hepatology (405 citations), Oncology (902 citations), Cancer Research (432 citations), Molecular Biology (1.5k citations) and Pathology and Forensic Medicine (398 citations). Alison Joly has collaborated with scholars based in United States, India and South Korea. Frequent co-authors include Michelle Chen, George F. Schreiner, Judith A. Abraham, Frauke Bentzien, F. Michael Yakes, Stefan Engst, Peiwen Yu, Andrew Lam, Fawn Qian and Jenny Tan. Their work appears in journals such as Endocrinology, Bioorganic & Medicinal Chemistry Letters, Biochemical Pharmacology, Journal of Biological Chemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact